Nicolaus Kröger

Research interests

Publications

• Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

  The Lancet Haematology · 2024 · https://doi.org/10.1016/s2352-3026(23)00342-3

• Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

  Bone Marrow Transplantation · 2022 · https://doi.org/10.1038/s41409-022-01691-w

• Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.12.003

• Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

  Bone Marrow Transplantation · 2021 · https://doi.org/10.1038/s41409-021-01227-8

• Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

  Bone Marrow Transplantation · 2021 · https://doi.org/10.1038/s41409-021-01227-8

• Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

  The Lancet Haematology · 2020 · https://doi.org/10.1016/s2352-3026(19)30256-x

• Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3 –Internal Tandem Duplication Mutation (SORMAIN)

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.19.03345

• Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

  Haematologica · 2019 · https://doi.org/10.3324/haematol.2019.229781

• Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019

  Bone Marrow Transplantation · 2019 · https://doi.org/10.1038/s41409-019-0516-2

• Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

  Leukemia · 2018 · https://doi.org/10.1038/s41375-018-0077-1

• Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report

  Bone Marrow Transplantation · 2017 · https://doi.org/10.1038/bmt.2017.34

• Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

  Blood · 2017 · https://doi.org/10.1182/blood-2016-06-724500

• Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1506002

• Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually

  Bone Marrow Transplantation · 2016 · https://doi.org/10.1038/bmt.2016.20

• Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015

  Bone Marrow Transplantation · 2015 · https://doi.org/10.1038/bmt.2015.6

• Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

  Leukemia · 2015 · https://doi.org/10.1038/leu.2015.212

• Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

  Blood · 2013 · https://doi.org/10.1182/blood-2013-03-488098

• Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice

  Bone Marrow Transplantation · 2013 · https://doi.org/10.1038/bmt.2013.107

• Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial

  The Lancet Oncology · 2012 · https://doi.org/10.1016/s1470-2045(12)70349-2

• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  Leukemia · 2011 · https://doi.org/10.1038/leu.2011.196

• Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.31.8436

• Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

  Leukemia · 2010 · https://doi.org/10.1038/leu.2010.60

• Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

  Blood · 2009 · https://doi.org/10.1182/blood-2009-07-234880

• Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients

  Bone Marrow Transplantation · 2003 · https://doi.org/10.1038/sj.bmt.1704291

• Evidence of a Graft-Versus-Leukemia Effect in Chronic Lymphocytic Leukemia After Reduced-Intensity Conditioning and Allogeneic Stem-Cell Transplantation: The Cooperative German Transplant Study Group

  Journal of Clinical Oncology · 2003 · https://doi.org/10.1200/jco.2003.12.011

Current projects

No projects listed.